Menu

Immunotherapy More Effective in Men: Study

Women with metastatic cancer who were treated with a checkpoint inhibitor had a smaller benefit than did men.

May 18, 2018
Kerry Grens

ISTOCK, MIRROR-IMAGESWomen given an immune checkpoint inhibitor to treat advanced cancer benefitted less from the drugs than men did, according to a meta-analysis of clinical trials involving more than 11,000 patients published this week (May 16) in The Lancet Oncology.

“Future research should guarantee greater inclusion of women in trials and focus on improving the effectiveness of immunotherapies in women, perhaps exploring different immunotherapeutic approaches in men and women,” the authors write in the study.

Checkpoint inhibitors work by taking the brakes off immune responses, and are known to improve the outcomes of patients with metastatic cancers. To see if checkpoint inhibitors affect men and women differently, the researchers collected the results of 20 clinical trials involving any of four of the drugs given to patients with either melanoma, renal cell carcinoma, urothelial cancer, head and neck cancer, or lung cancer.

While the immunotherapies boosted the chances for survival for men and women compared to patients who didn’t receive them, men saw a greater benefit. The hazard ratio, which describes the risk of dying, was 0.86 for women on checkpoint inhibitor therapy compared to women not taking the drugs, whereas for men taking checkpoint inhibitors the hazard ratio was 0.72—meaning they had a reduced risk of death compared to men not taking the drugs, and an even greater reduction compared to women on the drugs.

“[C]aution needs to be exercised before jumping directly to radical conclusions and before changing the current standard of care among approved indications for immune checkpoint inhibitors,” writes Omar Abdel-Rahman of Ain Shams University in an accompanying commentary. “Female patients who are otherwise indicated for treatment with any immune checkpoint inhibitor should not be denied treatment solely on the basis of these findings.”

See “Researchers Getting Smarter About Pairing Cancer Treatments”

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

Slice® Safety Cutters for Lab Work

Slice® Safety Cutters for Lab Work

Slice cutting tools—which feature our patent-pending safety blades—meet many lab-specific requirements. Our scalpels and craft knives are well suited for delicate work, and our utility knives are good for general use.

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.